The company shared new real-world findings for Aveir DR at the Asia Pacific Heart Rhythm Society (APHRS). These add to strong ...
Just a few weeks after Abbott presented the successful results of a trial of its Aveir DR dual-chamber leadless pacemaker system—data that it said had been promptly submitted for regulatory review—the ...
Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker The study successfully met all three of ...
Abbott ABT announced a favorable outcome on its leadless pacemaker. The company unveiled late-breaking results from the AVEIR dual-chamber (DR) i2i Investigational Device Exemption (IDE) study. The ...
The FDA has approved Abbott Laboratories' ABT AVEIR dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system to treat abnormal or slow heart rhythms. Through ...
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- A revolutionary advancement in cardiac care is changing what’s possible for people living with slow or abnormal heart rhythms. On October 13th, Abbott ...
(MASS APPEAL) – The first person in the United States has just received the world’s first dual chamber leadless pacemaker system. Pacemakers are designed to treat slow or abnormal heart rhythms. This ...
ABBOTT PARK, Ill., Nov. 12, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new, late-breaking data from the global Leadless II IDE study evaluating Abbott's investigational Aveir leadless ...
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- A revolutionary advancement in cardiac care is changing what’s possible for people living with slow or abnormal heart rhythms. On October 13th, Abbott ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback